Artwork

Content provided by Bryn Mawr Communications (BMC) and Retina Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Retina Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol AC

19:37
 
Share
 

Manage episode 429705128 series 2134816
Content provided by Bryn Mawr Communications (BMC) and Retina Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Retina Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinically relevant, and explore other risk factors that may be worthy of further investigation.

  continue reading

182 episodes

Artwork
iconShare
 
Manage episode 429705128 series 2134816
Content provided by Bryn Mawr Communications (BMC) and Retina Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Retina Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinically relevant, and explore other risk factors that may be worthy of further investigation.

  continue reading

182 episodes

Tất cả các tập

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide